Literature DB >> 8301055

Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?

P Andreone1, C Cursaro, G Gasbarrini.   

Abstract

Arachidonic acid metabolites seem to play an important role in modulating the post-receptorial activity of interferon-alpha. In this study the effect of interferon-alpha on prostaglandin E2 production was evaluated in cultured liver tissue in 18 patients with chronic active hepatitis related to viral infection (9 hepatitis B virus (HBV) and 9 hepatitis C virus (HCV) positive) and in 7 uninfected patients with various liver diseases. The results show that interferon-alpha induces a significant increase in prostaglandin E2 production in both HBV and HCV chronic active hepatitis. Since the inhibition of the cyclooxygenase pathway increases antiviral protein synthesis and prostaglandin E2 has an immunosuppressive activity, this finding seems to suggest that a combined therapy (interferon-alpha plus non-steroidal anti-inflammatory drugs) should be indicated at least for patients who do not respond to interferon therapy alone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8301055     DOI: 10.1016/s0168-8278(05)80576-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

1.  Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

Authors:  M Pirisi; C Fabris; P Toniutto; E Falleti; S G Tisminetzky; M Gerotto; G Soardo; D Vitulli; M Del Forno; F Baralle; E Bartoli
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

2.  Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.

Authors:  Myungsoo Joo; Young S Hahn; Minjae Kwon; Ruxana T Sadikot; Timothy S Blackwell; John W Christman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study.

Authors:  Annagiulia Gramenzi; Carmela Cursaro; Marzia Margotti; Clara Balsano; Alessandra Spaziani; Simona Anticoli; Elisabetta Loggi; Maddalena Salerno; Silvia Galli; Giuliano Furlini; Mauro Bernardi; Pietro Andreone
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.